CA2452558C - A synergistic pharmaceutical combination for the prevention or treatment of diabetes - Google Patents

A synergistic pharmaceutical combination for the prevention or treatment of diabetes Download PDF

Info

Publication number
CA2452558C
CA2452558C CA002452558A CA2452558A CA2452558C CA 2452558 C CA2452558 C CA 2452558C CA 002452558 A CA002452558 A CA 002452558A CA 2452558 A CA2452558 A CA 2452558A CA 2452558 C CA2452558 C CA 2452558C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acid addition
group
addition salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002452558A
Other languages
English (en)
French (fr)
Other versions
CA2452558A1 (en
Inventor
Zoltan Szilvassy
Gyoergy Rabloczky
Peter Literati Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
N-Gene Research Laboratories Inc
Original Assignee
N-Gene Research Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N-Gene Research Laboratories Inc filed Critical N-Gene Research Laboratories Inc
Priority to CA002682251A priority Critical patent/CA2682251A1/en
Publication of CA2452558A1 publication Critical patent/CA2452558A1/en
Application granted granted Critical
Publication of CA2452558C publication Critical patent/CA2452558C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
CA002452558A 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes Expired - Fee Related CA2452558C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002682251A CA2682251A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HUP0102982 2001-07-17
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
HUP0202204 2002-07-05
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002682251A Division CA2682251A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (2)

Publication Number Publication Date
CA2452558A1 CA2452558A1 (en) 2003-01-30
CA2452558C true CA2452558C (en) 2009-12-22

Family

ID=89980599

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002452558A Expired - Fee Related CA2452558C (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA002682251A Abandoned CA2682251A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002682251A Abandoned CA2682251A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (https=)
EP (1) EP1408966B1 (https=)
JP (1) JP4598390B2 (https=)
KR (1) KR100920560B1 (https=)
CN (1) CN1270713C (https=)
AT (1) ATE386523T1 (https=)
AU (1) AU2002354884B2 (https=)
BR (1) BR0210744A (https=)
CA (2) CA2452558C (https=)
CY (1) CY1107939T1 (https=)
DE (1) DE60225143T2 (https=)
DK (1) DK1408966T3 (https=)
ES (1) ES2300460T3 (https=)
IL (2) IL159412A0 (https=)
MX (1) MXPA04000324A (https=)
NO (1) NO20040153L (https=)
NZ (1) NZ531155A (https=)
PL (1) PL205826B1 (https=)
PT (1) PT1408966E (https=)
RU (1) RU2311907C2 (https=)
WO (1) WO2003007951A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
ES2357983T3 (es) * 2006-11-02 2011-05-04 N-Gene Research Laboratories Inc. Composición farmacéutica que presenta una actividad antipsicótica, antidepresiva o antiepiléptica con un efecto secundario reducido.
ZA200902760B (en) * 2006-11-02 2010-06-30 N-Gene Res Lab Inc Reduction of overweight or obesity
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
EA020870B1 (ru) 2007-07-19 2015-02-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
ES2638977T3 (es) * 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
CN103547588B (zh) 2011-04-13 2016-06-29 Isis制药公司 Ptp1b表达的反义调节
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
CA3067746A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
JP7536119B2 (ja) * 2020-05-27 2024-08-19 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイド受容体モジュレーターレラコリラントおよびｃｙｐ２ｃ９基質の併用投与
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
US8048873B2 (en) 2011-11-01
MXPA04000324A (es) 2004-07-23
DK1408966T3 (da) 2008-06-16
EP1408966B1 (en) 2008-02-20
US7635674B2 (en) 2009-12-22
CN1531433A (zh) 2004-09-22
CY1107939T1 (el) 2013-09-04
AU2002354884A2 (en) 2003-03-03
PL205826B1 (pl) 2010-05-31
WO2003007951A1 (en) 2003-01-30
NO20040153L (no) 2004-03-16
RU2004105149A (ru) 2005-04-20
IL159412A (en) 2009-09-22
RU2311907C2 (ru) 2007-12-10
PL364662A1 (en) 2004-12-13
KR20040029371A (ko) 2004-04-06
US20100048627A1 (en) 2010-02-25
KR100920560B1 (ko) 2009-10-08
ATE386523T1 (de) 2008-03-15
PT1408966E (pt) 2008-05-02
CA2682251A1 (en) 2003-01-30
NZ531155A (en) 2005-07-29
DE60225143T2 (de) 2009-02-12
JP4598390B2 (ja) 2010-12-15
IL159412A0 (en) 2004-06-01
AU2002354884B2 (en) 2007-10-18
CA2452558A1 (en) 2003-01-30
JP2004537550A (ja) 2004-12-16
ES2300460T3 (es) 2008-06-16
CN1270713C (zh) 2006-08-23
US20070015687A1 (en) 2007-01-18
BR0210744A (pt) 2004-07-20
DE60225143D1 (de) 2008-04-03
EP1408966A1 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
US8048873B2 (en) Synergistic pharmaceutical combination for the prevention or treatment of diabetes
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
US20060111428A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
KR100699757B1 (ko) 당뇨병성 신경병 치료용 의약의 제조를 위한 3-하이드록시-3-메틸글루타릴 조효소 α 환원효소 저해제의 용도
US20030139434A1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitor
JP2004537550A5 (https=)
ZA200308110B (en) Use of nk-1 receptor antagonists against benign prostatic hyperplasia
CA2522126A1 (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes
HRP960341A2 (en) New methods of using n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters)
JPWO1993005778A1 (ja) 血中脂質代謝改善剤
HUP0400762A2 (hu) Gyógyászati készítmény a diabetesz megelőzésére vagy kezelésére
US20090197917A1 (en) Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CN1840195A (zh) 一种用于预防或治疗糖尿病的协同药物组合物
EP1179345B1 (en) Inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160711